Deutsche Bank lowered the firm’s price target on Denali Therapeutics (DNLI) to $31 from $35 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics: Buy Rating Reiterated as TV Platform and Enzyme Portfolio Drive Long-Term Upside; $42 Price Target Maintained
- Denali, Biogen Halt Parkinson’s Trial After Efficacy Failure
- Denali Therapeutics trading resumes
- Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints
- Denali Therapeutics trading halted, news pending